Infinity Pharma (INFI) Misses Q1 EPS by 3c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Infinity Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Company Update
May 13, 2021 4:05 PM EDTUpdated TNBC data from MARIO-3 to be reported mid-year and 4Q21
Update for eganelisib in PD-L1 low, 2L advanced UC patients expected mid-year
$92M public offering strengthens balance sheet for continued development of eganelisib
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (Infinity or the Company), a clinical-stage biotechnology... More
